Shiga-ken, Japan

Hiroko Yoshino


Average Co-Inventor Count = 16.1

ph-index = 2

Forward Citations = 41(Granted Patents)


Location History:

  • Nara-ken, JP (2005)
  • Shiga-ken, JP (2010 - 2012)

Company Filing History:


Years Active: 2005-2012

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Hiroko Yoshino: Innovator in Pharmaceutical Chemistry

Introduction

Hiroko Yoshino is a notable inventor based in Shiga-ken, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target inflammatory and immunological disorders. With a total of 3 patents, his work has the potential to impact the treatment of various diseases.

Latest Patents

Yoshino's latest patents focus on arylsulfonamide derivatives that serve as CCR3 antagonists. These compounds are designed for use in pharmaceutical preparations aimed at treating conditions such as asthma, atopic dermatitis, and allergic rhinitis. The sulfonamide derivatives exhibit CCR3 antagonistic activity, making them valuable in the prophylaxis and treatment of diseases associated with CCR3 activity.

Career Highlights

Throughout his career, Hiroko Yoshino has worked with prominent companies in the pharmaceutical industry. Notable among these are Axikin Pharmaceuticals, Inc. and Bayer Aktiengesellschaft. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Yoshino has collaborated with several professionals in his field, including Norihiro Kawamura and Yingfu Li. These partnerships have likely enhanced his research and development efforts, leading to the successful creation of his patented compounds.

Conclusion

Hiroko Yoshino's contributions to pharmaceutical chemistry through his innovative patents demonstrate his commitment to advancing medical treatments. His work in developing CCR3 antagonists is particularly noteworthy, as it addresses critical health issues related to inflammatory and immunological disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…